FDA Rejects Promising Melanoma Drug Amid Leadership Turmoil
The FDA denied accelerated approval for a melanoma treatment that helped some patients, highlighting concerns over trial design and agency leadership under outgoing commissioner…
Archive 
NIH-backed tool improves pediatric amblyopia care access
A new NIH-supported online tool assists eye care providers in diagnosing and treating amblyopia, helping address specialist shortages across the U.S
Ebola Outbreak in Congo’s Ituri Province Kills Dozens, CDC Reports
Africa CDC confirms a new Ebola outbreak in eastern Congo with 246 suspected cases and 65 deaths, raising cross-border health concerns
MIT Develops mRNA Adjuvant to Boost T-Cell Response in Cancer Vaccines
MIT researchers created an mRNA-based vaccine adjuvant that significantly enhances T-cell activity, improving cancer tumor elimination and potentially strengthening infectious disease vaccines
FDA Finalizes Food Chemical Safety Review Program, Begins BHT and ADA Reassessments
The FDA launched a new program to systematically review food chemicals and has started reassessing the safety of additives BHT and ADA with public…
New Model Enhances Risk Prediction in Hypertrophic Cardiomyopathy
NIH-supported study shows combining cardiac MRI, blood biomarkers, and clinical data improves prediction of adverse events in hypertrophic cardiomyopathy patients
CDC Acting Director Says Hantavirus Risk Lower Than COVID-19
The CDC’s acting director said the hantavirus outbreak linked to a cruise ship is serious but does not pose the same public health threat…
FDA Seeks Input to Expand Drug Repurposing for Unmet Medical Needs
The FDA invites public feedback to identify new uses for approved drugs, aiming to accelerate treatments for diseases lacking effective options
WHO Chief Oversees Hantavirus Evacuation From Cruise Ship in Canary Islands
WHO Director-General Tedros Adhanom Ghebreyesus arrived in Tenerife to oversee evacuations of a cruise ship affected by a rare hantavirus outbreak
FDA Approves Bizengri for Rare NRG1 Fusion-Positive Cholangiocarcinoma
The FDA authorized Bizengri to treat adults with advanced cholangiocarcinoma with NRG1 gene fusion, marking the seventh approval under its National Priority Voucher pilot…